LB Phar­ma­ceu­ti­cals clos­es $75M Se­ries C as it be­gins PhII schiz­o­phre­nia tri­al

LB Phar­ma­ceu­ti­cals, a schiz­o­phre­nia biotech de­vel­op­ing a new ver­sion of a decades-old med­i­cine, has closed a $75 mil­lion Se­ries C raise and it be­gan a Phase II tri­al last month, a source fa­mil­iar with the com­pa­ny con­firmed to End­points News.

The New York City biotech has raised a to­tal of about $122 mil­lion since it was formed, per the source. The com­pa­ny had raised about $35 mil­lion last sum­mer and reached its ul­ti­mate $75 mil­lion Se­ries C tar­get this month.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER